Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function

Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function: Is it Better Than GFR?

This is a two phase study. The first part will take place at the National Institute of Cardiology in Mexico, the second phase will be made in collaboration with the University of California San Diego.

This is a non blind experimental study, 60 patients with different stages of CKD from the outpatient unit of the institute will be included. Each patient will receive a furosemide stress test of 1 mg/kg in non diuretic users and 1.5 mg/kg in diuretic users, in addition to an oral load of 5 grams of creatinine, as well as Iohexol to measure GFR. After the intervention blood and urine samples will be drawn at 10 minutes, 30 minutes, and every hour until the completion of the observation at 6 hours.

Blood and urine will be analized to measure creatinine (blood and urine), then samples will be processed for measurement of furosemide (mass spectometry), indoxyl sulphate, p-cresol, hippurate, and uromoduline.

The aim of this stiudy is to asses the differences between GFR and proximal tubule function.

Study Overview

• Status: Recruiting
• Conditions: Chronic Kidney Failure
• Intervention / Treatment: Drug: Furosemide

Detailed Description

Residual kidney function (RKF) its a critical tool in the CKD evolution and prognosis. It's well known that preserving RKF increases survival in patients with CKD.

Traditionally Glomerular Filtration Rate (GFR), and proteinuria have been the variables used to asses RKF, wich are glomerular residual function (GRF) variables. This glomerulocentric assestment of RKF has been challenged recently. It is knows that urea is not the principal uremic toxine, the protein boud uremic toxins are particullary important because it's elimination depends of the proximal tubular organic anionic transporters (OAT), and the organic cationic transporters (OCT). The functional integrity of this transporters are lost in advanced CKD stages, and it´s accumulation increases cardiovascular and renal damage because they activate proinflammatory citokines, increasing mortality, this was shown specially with the accumulation and clearance of hippurate and p-cresol independently of GFR.

The purpose of this study is to asses the functional capacity of two AOT (hOAT1, and hOAT3, that can be blocked by furosemide), and one OCT (OCT2 blocked by creatinine) using an stress test. The stress test will be performed in healthy subjects as well as in CKD from different stages. Protein bound uremic toxins such as indoxyl sulphate, p-cresol, and hippurate will be measured.

In the stress the typical furosemide stress test described previously by Mehta will be implemented, in addition to an oral load of 5 grams of creatinine oral load. This levels should be efficient enough to assess the functionality of the OCT2. A comparison between the tubular creatinine secretine to filtrated creatinine measuring GFR using Iohexol will be performed.

In conclusion this is a pilot study aimed to establish a practical methodology for the assesment of proximal tubular function.

• Study Type: Interventional
• Enrollment (Anticipated): 72
• Phase: Phase 3

Contacts and Locations

Study Locations

• Mexico
  • Mexico City, Mexico, 14080
    • Recruiting
    • Instituto Nacional De Cardiologia Ignacio Chavez
    • Contact: Magdalena Madero, MD; Phone Number: 1273 015555732911; Email: madero.magdalena@gmail.com
    • Contact: Armando Armenta, MD; Phone Number: 1273 015555732911; Email: ar.armenta89@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients older than 18 years old.
• Patients with CKD that attends to the outpatient clinic.
• Residual uresis of 500 mL

Exclusion Criteria:

• Patients younger than 18 years old.
• Increase of Cr in a rate of 0.5 mg/dL, or loss of more than 30% of previous GFR.
• Patients with cardiorrenal syndrome type 1.
• Patients with dilated miocardiopathy.
• Volume overload.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Healthy Kidney Donors; 12 Healthy Kidney Organ Donors	Drug: Furosemide; Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).; Oral creatinine load using 5 grams of creatinine; Other Names: Creatinine
Experimental: CKD Patients; 12 patients for each CKD Stage	Drug: Furosemide; Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).; Oral creatinine load using 5 grams of creatinine; Other Names: Creatinine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tubular Residual Kidney Function	To assess the functionallity of the HOAT1 and 3, as well OCT2 by stress test using furosemide and creatinine loads	1 year

Collaborators and Investigators

• Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez

Study record dates

Study Major Dates

• Study Start (Actual): March 3, 2020
• Primary Completion (Anticipated): December 1, 2021
• Study Completion (Anticipated): July 1, 2022

Study Registration Dates

• First Submitted: March 11, 2020
• First Submitted That Met QC Criteria: October 22, 2021
• First Posted (Actual): November 3, 2021

Study Record Updates

• Last Update Posted (Actual): November 3, 2021
• Last Update Submitted That Met QC Criteria: October 22, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Renal Insufficiency; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Natriuretic Agents; Membrane Transport Modulators; Diuretics; Sodium Potassium Chloride Symporter Inhibitors; Furosemide
• Other Study ID Numbers: 19-1131

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided
• IPD Plan Description: Will be decided in the future

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No